Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
18 avr. 2019 08h00 HE
|
Resverlogix Corp
CALGARY, Alberta, April 18, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that BETonMACE, the Company’s event-based, phase 3 registration...
Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study
15 avr. 2019 04h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin...
InCarda Therapeutics Appoints Daniel G. Welch as Executive Chairman of Board of Directors
03 avr. 2019 08h00 HE
|
InCarda Therapeutics, Inc.
SAN FRANCISCO, April 03, 2019 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases
01 avr. 2019 11h00 HE
|
Resverlogix Corp
CALGARY, Alberta, April 01, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic...
Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
18 mars 2019 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., March 18, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine
06 mars 2019 08h00 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
20 févr. 2019 07h30 HE
|
ARCA biopharma, Inc.
FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure population that has no FDA...
New Patent Issuances Strengthen InCarda Therapeutics’ Intellectual Property Portfolio Covering Novel Inhaled Cardiovascular Therapies
07 févr. 2019 08h05 HE
|
InCarda Therapeutics, Inc.
U.S. Patent Broadly Expands Coverage for Inhaled Treatment of Cardiovascular Disease to Include all Class I – IV Antiarrhythmic Drugs Additional U.S. Patent Provides Coverage for Combination of...
Leading BioSciences to Present at Biotech Showcase 2019
02 janv. 2019 08h05 HE
|
Leading BioSciences
CARLSBAD, Ca., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome™, today announced...
ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
20 déc. 2018 16h01 HE
|
ARCA biopharma, Inc.
Phase 3 atrial fibrillation trial planned in population with no effective or FDA approved therapiesPRECISION-AF, planned Phase 3 clinical trial in patients with genotype that responds most favorably...